The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogues

Samuel D. Banister,^{1,2*} Richard C. Kevin,³ Lewis Martin,³ Axel Adams,⁴ Christa Macdonald,⁵
Jamie J. Manning,⁵ Rochelle Boyd,⁶ Michael Cunningham,⁷ Marc Y. Stevens,⁸ Iain S.
McGregor,³ Michelle Glass,⁵ Mark Connor,⁶ and Roy R. Gerona⁴

¹School of Chemistry, The University of Sydney, NSW 2006, Australia; ²Department of Pathology, Stanford University, CA 94305, USA; ³School of Psychology, The University of Sydney, Camperdown, NSW 2005, Australia; ⁴Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, CA 94143, USA; ⁵School of Medical Sciences, The University of Auckland, Auckland, New Zealand; ⁶Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia; ⁷Division of Medicinal Chemistry, Department of Biomolecular Sciences, School of Pharmacy, The University of Mississippi, MS 38677, USA; ⁸Department of Radiology, Stanford University, CA 94305, USA.

*Corresponding author

Abstract: The structural diversity of synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) has increased since the first examples were reported a decade ago. 5F-PY-PICA and 5F-PY-PINACA were identified in 2015 as putative SCRA NPS, although nothing is known of their pharmacology. 5F-PY-PICA, 5F-PY-PINACA, and analogues intended to explore structure-activity relationships within this class of SCRA were synthesized and characterized by nuclear magnetic resonance spectroscopy and liquid chromatography–quadrupole time-of-flight–mass spectrometry. Using competitive binding experiments and fluorescence-based plate reader membrane potential assays, the affinities and activities of all analogues at cannabinoid type 1 and type 2 receptors (CB₁ and CB₂) were evaluated. All ligands showed minimal affinity for CB₁ ($pK_i < 5$), although several demonstrated moderate CB₂ binding ($pK_i = 5.45–6.99$). At 10 μ M none of the compounds produced an effect $> 50\%$ of CP55,950 at CB₁, while several compounds showed a slightly higher relative efficacy at CB₂. Unlike other SCRA NPS, 5F-PY-PICA and 5F-PY-PINACA did not produce cannabimimetic effects in mice at doses up to 10 mg/kg.

Keywords: cannabinoid, 5F-PY-PICA, 5F-PY-PINACA, pharmacology, mass spectrometry

Introduction: More than 800 new psychoactive substances (NPS) have been identified in the past decade, including more than 250 synthetic cannabinoid receptor agonists (SCRAs).^{1,2} The earliest SCRA NPS were 1-substituted 3-acylindoles, like JWH-018 (**1**, Fig. 1), and were based on research compounds with activity at cannabinoid type 1 and 2 (CB₁ and CB₂, respectively) receptors disclosed by academic laboratories or pharmaceutical companies.³⁻⁵ As acylindole SCRAs were prohibited in various jurisdictions, newer derivatives not yet subject to legislation such as AB-FUBINACA (**2**) and MDMB-CHMICA (**3**) appeared to replace them.^{6,7} SCRAs represent the largest and most chemically heterogeneous class of NPS, and new examples continue to emerge in drug markets around the world.⁸⁻¹³

Unlike early SCRA NPS, many recent SCRAs have no precedent in the scientific literature when first detected in drug markets, necessitating robust analytical workflows for identification.¹⁴ Even for the most well-studied SCRA NPS, existing data pertain to the activity of these compounds in cellular systems or animal models,¹⁵⁻¹⁸ with very few human studies reported.¹⁹ Of greater concern is the trend for increasing potency of SCRA NPS, with the most recent examples frequently associated with serious adverse effects including myocardial infarction, ischemic stroke, acute kidney injury, tonic-clonic convulsion, coma, and death.²⁰⁻³⁰

[APPROXIMATE PLACEMENT OF FIGURE 1]

The largest class of SCRA NPS are 1-substituted indole- and indazole-3-carboxamides. These typically feature secondary amides, as found in **2** and **3**, however, tertiary amides comprised of alicyclic or heterocyclic substituents have occasionally been reported. The earliest example was

piperazine derivative MEPIRAPIM (**4**), reported in Japan in 2014,³¹ likely inspired by a class of water-soluble cannabinoid analgesics developed by Schering-Plough.³² The first putative SCRA NPS featuring a pyrrolidine ring at the 3-position were recently reported; indole 5F-PY-PICA (**5**) was identified in France in June 2015,³³ and the indazole analogue 5F-PY-PINACA (**6**) was notified in Sweden around the same time.³³ The metabolic profile of 5F-PY-PICA in rat and human hepatocytes was recently described, but nothing else is known of the pharmacology of this class of putative SCRA NPS.³⁴

Although there are obvious structural similarities to MEPIRAPIM, neither 5F-PY-PICA nor 5F-PY-PINACA had been described in the chemical literature prior to their detection on the NPS market. Pyrrolidine is a pendant structural feature of many psychoactive cathinones,³⁵ but 1-(5-fluoropentyl)-1*H*-ind(az)ole-3-carboxamide is a common structural motif in SCRA NPS. The recent discovery in Spain of a phenethylamine featuring a popular SCRA functional group suggests that the design of NPS may not follow conventional rules for drug design, or that molecular hybridization is used in an ad hoc fashion to generate new compounds.³⁶

Since nothing is known of the chemistry or pharmacology of 5F-PY-PICA and 5F-PY-PINACA, the aim of the present work was to prepare and analytically characterize these emergent SCRA and several “prophetic” analogues, and to evaluate their cannabinoid receptor affinities and activities *in vitro* and *in vivo*. Related analogues arising from expansion (**7**, **8**), or scission (**9**, **10**) of the pyrrolidine ring were also prepared and evaluated to provide insight into structure-activity relationships (SARs) for this class. Additionally, several 5F-PY-PICA analogues featuring alternative 1-indole substituents commonly found in other SCRA classes were also prepared and

characterized proactively. Specifically, analogues featuring a butyl (**11**), pentyl (**12**), 4-fluorobenzyl (**13**), and cyclohexylmethyl (**14**) subunit were synthesized, based on current SCRA design trends.

Experimental. General chemical synthesis details. All reactions were performed under an atmosphere of nitrogen or argon unless otherwise specified. Dichloromethane, *N,N*-dimethylformamide (DMF), methanol, and toluene were anhydrous and used as purchased. Triethylamine was distilled over calcium hydride. All other commercially available reagents (Sigma-Aldrich) were used as purchased. Analytical thin layer chromatography (TLC) was performed using Merck aluminum-backed silica gel 60 F254 (0.2 mm) plates which were visualized using shortwave (254 nm) ultra-violet fluorescence. Flash chromatography was performed using Merck Kieselgel 60 (230–400 mesh) silica gel. Melting points were measured in open capillaries using an Laboratory Devices Mel-Temp II and are uncorrected. Nuclear magnetic resonance spectra were recorded at 298 K or 308 K using a Agilent 400 MHz spectrometer. The data are reported as chemical shift (δ ppm) relative to the residual protonated solvent resonance, relative integral, multiplicity (s = singlet, br = broad singlet, d = doublet, t = triplet, q = quartet, quin. = quintet, m = multiplet), coupling constants (*J* Hz) and assignment. Assignment of signals was assisted by COSY, DEPT, HSQC, and HMBC experiments where necessary. For compounds containing saturated heterocyclic amides (**5–8**, **11–14**), severe exchange broadening of the amide α - and β -carbon signals was observed, consistent with previous characterization of analogous systems.³⁷

General procedure for amidation of 1-alkyl-1*H*-indole-3-carboxylic acids. A solution of the appropriate carboxylic acid (0.5 mmol) in CH₂Cl₂ (1 mL) was treated with (COCl)₂ (85 μL, 1.0 mmol, 2.0 equiv.) followed by DMF (1 drop). After stirring for 2 h, the solution was evaporated *in vacuo*, and the crude acid chloride was used immediately in the following step.

A cooled (0 °C) solution of the freshly prepared acid chloride (0.5 mmol) in CH₂Cl₂ (5 mL) was treated with Et₃N (175 μL, 1.25 mmol, 2.5 equiv.), the appropriate amine (0.60 mmol, 1.2 equiv.), and stirred at ambient temperature for 14 h. The mixture was partitioned between CH₂Cl₂ (20 mL) and 1 M aq. HCl (10 mL). The layers were separated and the organic phase was washed with 1 M aq. HCl (2 × 10 mL), sat. aq. NaHCO₃ (3 × 10 mL), brine (10 mL), dried (MgSO₄), and the solvent evaporated under reduced pressure. The crude products were purified by flash chromatography unless stated otherwise.

(1-(5-Fluoropentyl)-1*H*-indol-3-yl)(pyrrolidin-1-yl)methanone (5, 5F-PY-PICA). Treating 1-(5-fluoropentyl)-1*H*-indole-3-carboxylic acid (125 mg, 0.5 mmol) with pyrrolidine (50 μL, 0.60 mmol, 1.2 equiv.) according to the general procedure afforded, following purification by flash chromatography (EtOAc), **5** as a white solid (135 mg, 89%). m.p. 66–68 °C; R_f 0.41 (EtOAc); ¹H NMR (400 MHz, CDCl₃): δ 8.15–8.12 (1H, m, CH), 7.41 (1H, s, CH), 7.34–7.31 (1H, m, CH), 7.26 (1H, td, *J* = 7.5, 1.3 Hz, CH), 7.21 (1H, ddd, *J* = 7.9, 6.9, 1.2 Hz, CH), 4.41 (2H, dt, ²*J*_{HF} = 47.3 Hz, ³*J*_{HH} = 5.9 Hz, CH₂F), 4.15 (2H, t, *J* = 7.1 Hz, CH₂), 3.69 (4H, t, *J* = 6.6 Hz, CH₂), 1.98–1.87 (6H, m, CH₂), 1.77–1.64 (2H, m, CH₂), 1.49–1.42 (2H, m, CH₂); ¹³C NMR (100 MHz, CDCl₃): δ 165.5 (CO), 135.9 (C_{quat.}), 129.5 (CH), 127.7 (C_{quat.}), 122.6 (CH), 122.5 (CH), 121.1 (CH), 111.7 (C_{quat.}), 109.5 (CH), 83.8 (d, ¹*J*_{CF} = 165.2 Hz, CH₂F), 47.7 (br, 2 × CH₂), 46.7 (CH₂), 30.1 (d, ²*J*_{CF}

= 19.8 Hz, CH₂), 29.8 (CH₂), 25.5 (br, 2 × CH₂), 23.0 (d, ³J_{CF} = 5.0 Hz, CH₂); HRMS (ESI) *m/z* calcd for C₁₈H₂₃N₂O₂F, 302.1794, found 302.1793. All physical properties and spectral data were consistent with those reported.³⁸

(1-(5-Fluoropentyl)-1*H*-indazol-3-yl)(pyrrolidin-1-yl)methanone (6, 5F-PY-PINACA). To a solution of 1-(5-fluoropentyl)-1*H*-indazole-3-carboxylic acid (125 mg, 0.50 mmol) in DMF (2.5 mL) was added HOBt·H₂O (84 mg, 0.55 mmol, 1.1 equiv.), EDC·HCl (125 mg, 0.65 mmol, 1.3 equiv.), pyrrolidine (42 μL, 0.50 mmol, 1.0 equiv.), and Et₃N (140 μL, 1.00 mmol, 2.0 equiv.), and the mixture stirred at ambient temperature for 13 h. The mixture was poured onto H₂O (200 mL), extracted with EtOAc (3 × 25 mL), and the combined organic were washed with H₂O (2 × 25 mL), brine (25 mL), dried (MgSO₄), and the solvent evaporated under reduced pressure. The crude material was purified using flash chromatography (hexane-EtOAc, 50:50) to give **6** as a colorless oil (137 mg, 90%). *R*_f 0.41 (hexane-EtOAc, 50:50); ¹H NMR (400 MHz, CDCl₃): δ 8.36 (1H, dt, *J* = 8.2, 1.0 Hz, CH), 7.40 (1H, t, *J* = 1.0 Hz, CH), 7.39 (1H, d, *J* = 1.0 Hz, CH), 7.26-7.22 (1H, m, CH), 4.409 (2H, t, *J* = 7.0 Hz, CH₂), 4.408 (2H, dt, ²J_{HF} = 47.3 Hz, ³J_{HH} = 6.0 Hz, CH₂F), 4.02 (2H, t, *J* = 6.6 Hz, CH₂), 3.75 (2H, t, *J* = 6.7 Hz, CH₂), 2.04-1.90 (6H, m, CH₂), 1.79-1.66 (2H, m, CH₂), 1.50-1.42 (2H, m, CH₂); ¹³C NMR (100 MHz, CDCl₃): δ 162.5 (CO), 140.1 (C_{quat}), 139.2 (C_{quat}), 126.7 (CH), 124.7 (C_{quat}), 123.6 (CH), 122.2 (CH), 108.8 (CH), 83.8 (d, ¹J_{CF} = 165.2 Hz, CH₂F), 49.1 (CH₂), 49.0 (CH₂), 46.9 (CH₂), 30.1 (d, ²J_{CF} = 19.8 Hz, CH₂), 29.4 (CH₂), 26.8 (CH₂), 24.1 (CH₂), 22.8 (d, ³J_{CF} = 5.2 Hz, CH₂); HRMS (ESI) *m/z* calcd for C₁₇H₂₂N₃O₂F, 303.1747, found 303.1746. All physical properties and spectral data were consistent with those reported.³⁹

(1-(5-Fluoropentyl)-1*H*-indol-3-yl)(piperidin-1-yl)methanone (7). Treating 1-(5-fluoropentyl)-1*H*-indole-3-carboxylic acid (125 mg, 0.5 mmol) with piperidine (60 μ L, 0.60 mmol, 1.2 equiv.) according to the general procedure gave, following purification by flash chromatography (hexane-EtOAc 50:50), **7** as a colorless oil (125 mg, 79%). R_f 0.56 (EtOAc); ^1H NMR (400 MHz, CDCl_3 , 308 K): δ 7.71 (1H, ddd, $J = 7.9, 1.4, 0.8$ Hz, CH), 7.41 (1H, s, CH), 7.35-7.33 (1H, m, CH), 7.26-7.22 (1H, m, CH), 7.18 (1H, ddd, $J = 8.0, 7.0, 1.1$ Hz, CH), 4.41 (2H, dt, $^2J_{\text{HF}} = 47.3$ Hz, $^3J_{\text{HH}} = 6.0$ Hz, CH_2F), 4.14 (2H, t, $J = 7.1$ Hz, CH_2), 3.67-3.64 (4H, m, CH_2), 1.92 (2H, quin., $J = 7.5$ Hz, CH_2), 1.78-1.59 (8H, m, CH_2), 1.51-1.43 (2H, m, CH_2); ^{13}C NMR (100 MHz, CDCl_3 , 308 K): δ 166.6 (CO), 135.9 ($\text{C}_{\text{quat.}}$), 130.1 (CH), 126.5 ($\text{C}_{\text{quat.}}$), 122.3 (CH), 121.0 (CH), 120.8 (CH), 111.4 ($\text{C}_{\text{quat.}}$), 109.8 (CH), 83.7 (d, $^1J_{\text{CF}} = 165.3$ Hz, CH_2F), 46.6 (CH_2), 46.3 (br, $2 \times \text{CH}_2$), 30.1 (d, $^2J_{\text{CF}} = 19.8$ Hz, CH_2), 29.8 (CH_2), 26.5 (br, $2 \times \text{CH}_2$), 24.9 (CH_2), 23.0 (d, $^3J_{\text{CF}} = 5.0$ Hz, CH_2); HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{25}\text{N}_2\text{OF}$, 316.1951, found 316.1953.

Azepan-1-yl(1-(5-fluoropentyl)-1*H*-indol-3-yl)methanone (8). Treating 1-(5-fluoropentyl)-1*H*-indole-3-carboxylic acid (125 mg, 0.5 mmol) with homopiperidine (65 μ L, 0.60 mmol, 1.2 equiv.) according to the general procedure gave, following purification by flash chromatography (hexane-EtOAc 50:50), **8** (130 mg, 79%) as a colorless oil. R_f 0.63 (EtOAc); ^1H NMR (400 MHz, CDCl_3 , 308 K): δ 7.82 (1H, dt, $J = 7.8, 1.1$ Hz, CH), 7.34-7.31 (2H, m, CH, overlapping), 7.24 (1H, ddd, $J = 8.2, 7.0, 1.3$ Hz, CH), 7.17 (1H, ddd, $J = 8.0, 7.0, 1.1$ Hz, CH), 4.40 (2H, dt, $^2J_{\text{HF}} = 47.3$ Hz, $^3J_{\text{HH}} = 6.0$ Hz, CH_2F), 4.13 (2H, t, $J = 7.1$ Hz, CH_2), 3.70-3.67 (4H, m, CH_2), 1.90 (2H, quin., $J = 7.5$ Hz, CH_2), 1.83-1.58 (10H, m, CH_2), 1.49-1.42 (2H, m, CH_2); ^{13}C NMR (100 MHz, CDCl_3 , 308 K): δ 167.3 (CO), 135.8 ($\text{C}_{\text{quat.}}$), 128.5 (CH), 127.2 ($\text{C}_{\text{quat.}}$), 122.4 (CH), 121.5 (CH), 120.7 (CH), 111.5 ($\text{C}_{\text{quat.}}$), 109.6 (CH), 83.7 (d, $^1J_{\text{CF}} = 165.3$ Hz, CH_2F), 48.1 (br, $2 \times \text{CH}_2$), 46.6 (CH_2),

30.0 (d, $^2J_{\text{CF}} = 19.8$ Hz, CH₂), 29.8 (CH₂), 28.7 (br, $2 \times \text{CH}_2$), 27.6 (br, $2 \times \text{CH}_2$), 23.0 (d, $^3J_{\text{CF}} = 5.0$ Hz, CH₂); HRMS (ESI) m/z calcd for C₂₀H₂₇N₂O₂F, 330.2107, found 330.2113.

1-(5-Fluoropentyl)-*N,N*-diethyl-1*H*-indole-3-carboxamide (9). Treating 1-(5-fluoropentyl)-1*H*-indole-3-carboxylic acid (125 mg, 0.5 mmol) with diethylamine (60 μL , 0.60 mmol, 1.2 equiv.) according to the general procedure gave, following purification by flash chromatography (EtOAc), **9** (125 mg, 82%) as a colorless oil. R_f 0.61 (EtOAc); ^1H NMR (400 MHz, CDCl₃, 308 K): δ 7.77 (1H, ddd, $J = 7.9, 1.3, 0.8$ Hz, CH), 7.33 (1H, dt, $J = 8.2, 0.9$ Hz, CH, overlapping), 7.32 (1H, s, CH, overlapping), 7.24 (1H, ddd, $J = 8.2, 7.0, 1.3$ Hz, CH), 7.18 (1H, ddd, $J = 7.9, 7.0, 1.0$ Hz, CH), 4.41 (2H, dt, $^2J_{\text{HF}} = 47.3$, $^3J_{\text{HH}} = 5.9$ Hz, CH₂F), 4.15 (2H, t, $J = 7.1$ Hz, NCH₂), 3.57 (4H, q, $J = 7.1$ Hz, $2 \times \text{NCH}_2$), 1.91 (2H, quin., $J = 7.5$ Hz, CH₂), 1.78-1.65 (2H, m, CH₂), 1.50-1.43 (2H, m, CH₂), 1.22 (6H, t, $J = 7.1$ Hz, $2 \times \text{CH}_3$); ^{13}C NMR (100 MHz, CDCl₃, 308 K): δ 167.0 (CO), 135.9 (C_{quat.}), 128.3 (CH), 127.1 (C_{quat.}), 122.5 (CH), 121.2 (CH), 120.7 (CH), 111.6 (C_{quat.}), 109.7 (CH), 83.8 (d, $^1J_{\text{CF}} = 165.2$ Hz, CH₂F), 46.6 (CH₂), 41.5 (br, $2 \times \text{CH}_2$), 30.1 (d, $^2J_{\text{CF}} = 19.8$ Hz, CH₂), 29.9 (CH₂), 23.0 (d, $^3J_{\text{CF}} = 5.0$ Hz, CH₂), 14.0 ($2 \times \text{CH}_3$); HRMS (ESI) m/z calcd for C₁₈H₂₅N₂O₂F, 304.1951, found 304.1953.

1-(5-Fluoropentyl)-*N,N*-dimethyl-1*H*-indole-3-carboxamide (10). Treating 1-(5-fluoropentyl)-1*H*-indole-3-carboxylic acid (125 mg, 0.5 mmol) with a solution of dimethylamine in THF (2 M, 300 μL , 0.60 mmol, 1.2 equiv.) according to the general procedure gave, following purification by flash chromatography (EtOAc), **10** (116 mg, 84%) as a colorless oil. R_f 0.31 (EtOAc); ^1H NMR (400 MHz, CDCl₃, 308 K): δ 7.79 (1H, ddd, $J = 7.9, 1.4, 0.9$ Hz, CH), 7.41 (1H, s, CH), 7.34 (1H, dt, $J = 8.2, 0.9$ Hz, CH), 7.25 (1H, ddd, $J = 8.2, 6.9, 1.3$ Hz, CH), 7.20 (1H, ddd, $J = 7.9, 6.9, 1.3$

Hz, CH), 4.42 (2H, dt, $J = 47.3, 5.9$ Hz, CH₂F), 4.15 (2H, t, $J = 7.1$ Hz, NCH₂), 3.16 (6H, s, 2 × CH₃), 1.95 (2H, quin. $J = 7.5$ Hz, CH₂), 1.78-1.65 (2H, m, CH₂), 1.51-1.43 (2H, m, CH₂); ¹³C NMR (100 MHz, CDCl₃, 308 K): δ 167.8 (CO), 135.9 (C_{quat.}), 130.0 (CH), 126.9 (C_{quat.}), 122.5 (CH), 121.6 (CH), 120.9 (CH), 111.1 (C_{quat.}), 109.8 (CH), 83.8 (d, $^1J_{CF} = 165.2$ Hz, CH₂F), 46.7 (NCH₂), 37.8 (br, 2 × CH₃), 30.1 (d, $^2J_{CF} = 19.8$ Hz, CH₂), 29.9 (CH₂), 23.0 (d, $^3J_{CF} = 5.0$ Hz, CH₂); HRMS (ESI) m/z calcd for C₁₆H₂₁N₂O₂F, 276.1638, found 276.1643.

(1-Butyl-1*H*-indol-3-yl)(pyrrolidin-1-yl)methanone (11). Treating 1-butyl-1*H*-indole-3-carboxylic acid (109 mg, 0.5 mmol) with pyrrolidine (45 μ L, 0.55 mmol, 1.1 equiv.) according to the general procedure gave, following purification by flash chromatography (EtOAc), **11** (113 mg, 84%) as colorless crystals. m.p. 102.5–104.5 °C; R_f 0.41 (EtOAc); ¹H NMR (400 MHz, CDCl₃, 308 K): δ 8.14 (1H, ddd, $J = 7.8, 1.5, 0.8$ Hz, CH), 7.41 (1H, s, CH), 7.34-7.31 (1H, m, CH), 7.24 (1H, ddd, $J = 8.1, 6.9, 1.4$ Hz, CH), 7.20 (1H, ddd, $J = 8.1, 6.8, 1.4$ Hz, CH), 4.12 (2H, t, $J = 7.1$ Hz, CH₂), 3.70-3.67 (4H, m, CH₂), 1.97-1.90 (4H, m, CH₂), 1.86-1.79 (2H, m, CH₂), 1.40-1.31 (2H, m, CH₂), 0.94 (3H, t, $J = 7.4$ Hz, CH₃); ¹³C NMR (100 MHz, CDCl₃, 308 K): δ 165.5 (CO), 135.9 (C_{quat.}), 129.6 (CH), 127.7 (C_{quat.}), 122.5 (CH), 122.4 (CH), 120.9 (CH), 111.4 (C_{quat.}), 109.5 (CH), 47.8 (br, 2 × CH₂), 46.6 (CH₂), 32.2 (CH₂), 25.7 (br, 2 × CH₂), 20.2 (CH₂), 13.7 (CH₃); HRMS (ESI) m/z calcd for C₁₇H₂₂N₂O, 270.1732, found 270.1734.

(1-Pentyl-1*H*-indol-3-yl)(pyrrolidin-1-yl)methanone (12). Treating 1-pentyl-1*H*-indole-3-carboxylic acid (116 mg, 0.5 mmol) with pyrrolidine (45 μ L, 0.55 mmol, 1.1 equiv.) according to the general procedure gave, following purification by flash chromatography (EtOAc), **12** (89 mg, 63%) as colorless crystals. m.p. 57–59 °C; R_f 0.37 (EtOAc); ¹H NMR (400 MHz, CDCl₃, 308 K):

δ 8.15-8.12 (1H, m, CH), 7.41 (1H, s, CH), 7.34-7.32 (1H, m, CH), 7.25 (1H, ddd, J = 8.1, 7.0, 1.4 Hz, CH), 7.20 (1H, ddd, J = 8.0, 6.9, 1.3 Hz, CH), 4.12 (2H, t, J = 7.2 Hz, CH₂), 3.75-3.64 (4H, m, CH₂), 1.99-1.90 (4H, m, CH₂), 1.86 (2H, quin., J = 7.2 Hz, CH₂), 1.39-1.27 (4H, m, CH₂), 0.89 (3H, t, J = 7.0 Hz, CH₃); ¹³C NMR (100 MHz, CDCl₃, 308 K): δ 165.6 (CO), 135.9 (C_{quat.}), 129.6 (CH), 127.7 (C_{quat.}), 122.5 (CH), 122.4 (CH), 121.0 (CH), 111.5 (C_{quat.}), 109.6 (CH), 47.9 (br, 2 $\times$ CH₂), 46.9 (CH₂), 29.9 (CH₂), 29.2 (CH₂), 25.6 (br, 2 $\times$ CH₂), 22.4 (CH₂), 14.0 (CH₃); HRMS (ESI) m/z calcd for C₁₈H₂₄N₂O, 284.1889, found 284.1889.

(1-(4-Fluorobenzyl)-1*H*-indol-3-yl)(pyrrolidin-1-yl)methanone (13). Treating 1-(4-fluorobenzyl)-1*H*-indole-3-carboxylic acid (135 mg, 0.5 mmol) with pyrrolidine (45 μ L, 0.55 mmol, 1.1 equiv.) according to the general procedure gave, following purification by flash chromatography (EtOAc), **13** (129 mg, 80%) as a white solid. m.p. 159–161 °C; R_f 0.33 (EtOAc); ¹H NMR (400 MHz, CDCl₃, 308 K): δ 8.17-8.13 (1H, m, CH), 7.41 (1H, m, CH), 7.27-7.20 (3H, m, CH), 7.12-7.07 (2H, m, CH), 7.02-6.96 (2H, m, CH), 5.30 (2H, s, CH₂), 3.67 (4H, br s, CH₂), 1.97-1.90 (4H, m, CH₂); ¹³C NMR (100 MHz, CDCl₃, 308 K): δ 165.3 (CO), 162.6 (d, ¹ J_{CF} = 247.0 Hz, CF), 136.1 (C_{quat.}), 132.4 (d, ⁴ J_{CF} = 3.5 Hz, C_{quat.}), 129.7 (CH), 128.7 (d, ³ J_{CF} = 8.1 Hz, CH), 127.8 (C_{quat.}), 123.0 (CH), 122.5 (CH), 121.4 (CH), 116.0 (d, ² J_{CF} = 21.9 Hz, CH), 112.4 (C_{quat.}), 109.8 (CH), 49.9 (CH₂), 48.0 (br, 2 $\times$ CH₂), 25.7 (br, 2 $\times$ CH₂); HRMS (ESI) m/z calcd for C₂₀H₁₉N₂OF, 322.1481, found 322.1484.

(1-(Cyclohexylmethyl)-1*H*-indol-3-yl)(pyrrolidin-1-yl)methanone (14). Treating 1-(cyclohexylmethyl)-1*H*-indole-3-carboxylic acid (129 mg, 0.5 mmol) with pyrrolidine (45 μ L, 0.55 mmol, 1.1 equiv.) according to the general procedure gave, following purification by flash

chromatography (EtOAc), **14** (130 mg, 84%) as a white solid. m.p. 156–158 °C; R_f 0.39 (EtOAc); ^1H NMR (400 MHz, CDCl_3 , 308 K): δ 8.14 (1H, ddd, $J = 7.8, 1.5, 0.8$ Hz, CH), 7.37 (1H, s, CH), 7.34–7.31 (1H, m, CH), 7.27–7.22 (1H, m, CH), 7.21–7.18 (1H, m, CH), 3.95 (2H, d, $J = 7.2$ Hz, CH_2), 3.73–3.66 (4H, m, CH_2), 1.97–1.93 (4H, m, CH_2), 1.90–1.81 (1H, m, CH), 1.76–1.61 (5H, m, CH_2), 1.25–1.10 (3H, m, CH_2), 1.06–0.95 (2H, m, CH_2); ^{13}C NMR (100 MHz, CDCl_3 , 308 K): δ 165.6 (CO), 136.3 (C_{quat}), 130.4 (CH), 127.7 (C_{quat}), 122.5 (CH), 122.4 (CH), 121.0 (CH), 111.2 (C_{quat}), 109.8 (CH), 53.4 (CH_2), 47.8 (br, $2 \times \text{CH}_2$), 38.8 (CH), 31.2 ($2 \times \text{CH}_2$), 26.4 (CH_2), 25.9 (br, $2 \times \text{CH}_2$), 25.8 ($2 \times \text{CH}_2$); HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}$, 310.2045, found 310.2048.

General procedure for synthesis of 1-alkyl-1*H*-indole-3-carboxylic acids. To a cooled (0 °C) suspension of sodium hydride (60% dispersion in mineral oil, 120 mg, 3.00 mmol, 2.0 equiv.) in DMF (1.5 mL) was added dropwise a solution of indole (**15**, 176 mg, 1.50 mmol) in DMF (0.2 mL) and the mixture allowed to stir at ambient temperature for 10 min. The mixture was cooled (0 °C), treated dropwise with the appropriate alkyl bromide (1.58 mmol, 1.05 equiv.), and stirred at ambient temperature for 1 h. The mixture was cooled (0 °C), treated portionwise with trifluoroacetic anhydride (0.521 mL, 3.75 mmol, 2.5 equiv.), and stirred at ambient temperature for 1 h. The solution was poured portionwise onto vigorously stirred ice-water (90 mL) until precipitation was complete, and the red-pink solid was filtered and air dried overnight.

To a refluxing solution of potassium hydroxide (278 mg, 4.95 mmol, 3.3 equiv.) in methanol (0.55 mL) was added portionwise a solution of the crude 1-alkyl-3-trifluoroacetyl-1*H*-indole in toluene (1.25 mL) and the solution heated at reflux for 2 h. The solution was cooled to ambient temperature and partitioned between 1 M aq. NaOH (40 mL) and Et_2O (5 mL). The layers were separated and

the aqueous layer was adjusted to pH 1 with 10 M aq. HCl. The aqueous phase was extracted with Et₂O (3 × 10 mL), dried (Na₂SO₄), and solvent evaporated under reduced pressure. The crude products were recrystallized from *i*-PrOH unless otherwise stated.

1-Butyl-1*H*-indole-3-carboxylic acid (16). Subjecting 1-bromobutane (170 μL, 1.58 mmol) to the general procedure above gave **16** as a colorless crystalline solid (201 mg, 62% over 2 steps). m.p. 134–135 °C; ¹H NMR (400 MHz, CDCl₃, 298 K): δ 8.28–8.23 (1H, m, CH), 7.93 (1H, s, CH), 7.42–7.37 (1H, m, CH), 7.33–7.29 (2H, m, CH), 4.17 (2H, d, *J* = 7.1 Hz, CH₂), 1.92–1.84 (2H, m, CH₂), 1.43–1.33 (2H, m, CH₂), 0.97 (3H, t, *J* = 7.4 Hz, CH₃); All spectral data were consistent with those previously reported.⁴⁰

1-Pentyl-1*H*-indole-3-carboxylic acid (17). Subjecting 1-bromopentane (195 μL, 1.58 mmol) to the general procedure gave **17** as a colorless crystalline solid (192 mg, 55% over 2 steps). m.p. 106–108 °C (lit. m.p. 106–108 °C); ¹H NMR (400 MHz, CDCl₃, 298 K): δ 8.30–8.26 (1H, m, CH), 7.94 (1H, s, CH), 7.41–7.38 (1H, m, CH), 7.34–7.29 (2H, m, CH), 4.16 (2H, d, *J* = 7.2 Hz, CH₂), 1.90 (2H, quin., *J* = 7.2 Hz, CH₂), 1.40–1.30 (4H, m, CH₂), 0.91 (3H, t, *J* = 7.4 Hz, CH₃). All physical properties and spectral data were consistent with those reported.⁴¹

1-(5-Fluoropentyl)-1*H*-indole-3-carboxylic acid (18). Subjecting 1-bromo-5-fluoropentane (195 μL, 1.58 mmol) to the general procedure gave **18** as a colorless crystalline solid (247 mg, 66% over 2 steps). m.p. 120–122 °C (lit. m.p. 120–122 °C); ¹H NMR (400 MHz, CDCl₃, 298 K): δ 8.29–8.25 (1H, m, CH), 7.93 (1H, s, CH), 7.41–7.37 (1H, m, CH), 7.34–7.30 (2H, m, CH), 4.43 (2H, dt, ²*J*_{CF} = 47.3 Hz, ³*J*_{HH} = 5.9 Hz, CH₂F), 4.18 (2H, d, *J* = 7.1 Hz, CH₂), 1.98–1.91 (2H, m,

CH₂), 1.79-1.66 (2H, m, CH₂), 1.52-1.44 (2H, m, CH₂). All physical properties and spectral data were consistent with those reported.⁴²

1-(4-Fluorobenzyl)-1*H*-indole-3-carboxylic acid (19). Subjecting 4-fluorobenzyl bromide (195 μL, 1.58 mmol) to the general procedure gave **19** as a colorless crystalline solid (256 mg, 63% over 2 steps). m.p. 208–210 °C (lit. m.p. 207–209 °C); ¹H NMR (400 MHz, CDCl₃, 298 K): δ 8.26-8.24 (1H, m, CH), 7.92 (1H, s, CH), 7.34-7.26 (3H, m, CH), 7.18-7.14 (2H, m, CH), 7.06-7.00 (2H, m, CH), 5.33 (2H, s, CH₂). All physical properties and spectral data were consistent with those reported.⁴³

1-(Cyclohexylmethyl)-1*H*-indole-3-carboxylic acid (20). Subjecting (bromomethyl)cyclohexane (220 μL, 1.58 mmol) to the general procedure gave **20** as a colorless crystalline solid (174 mg, 45%). m.p. 180–182 °C (lit. m.p. 180–182 °C); ¹H NMR (400 MHz, CDCl₃, 298 K): δ 8.27-8.23 (1H, m, CH), 7.89 (1H, s, CH), 7.40-7.36 (1H, m, CH), 7.32-7.28 (2H, m, CH), 3.99 (2H, d, *J* = 7.2 Hz, CH₂), 1.95-1.85 (1H, m, CH), 1.76-1.62 (5H, m, CH₂), 1.26-1.15 (3H, m, CH₂), 1.06-0.97 (2H, m, CH₂). All physical properties and spectral data were consistent with those reported.⁴³

Methyl 1-(5-fluoropentyl)-1*H*-indazole-3-carboxylate (22). To a cooled (0 °C) solution of methyl 1*H*-indazole-3-carboxylate (**21**, 176 mg, 1.00 mmol, 1.0 equiv.) in THF (5.0 mL) was added dropwise a 1 M solution of potassium tert-butoxide in THF (1.1 mL, 1.1 mmol, 1.1 equiv.), and the solution stirred at ambient temperature for 1 h. The solution was cooled (0 °C), treated dropwise with 1-bromo-5-fluoropentane (130 μL, 1.05 mmol, 1.05 equiv.), and stirred at ambient

temperature for 14 h. The mixture was partitioned between EtOAc (10 mL) and H₂O (30 mL) and the layers separated. The aqueous layer was extracted with EtOAc (3 × 10 mL), and the combined organic phases were washed with brine (10 mL), dried (Na₂SO₄), and the solvent evaporated under reduced pressure affording, following purification by flash chromatography (hexane-EtOAc, 90:10), **22** (214 mg, 81%) as a colorless oil. *R*_f 0.59 (hexane-EtOAc, 80:20); ¹H NMR (400 MHz, CDCl₃, 298 K): δ 8.20 (1H, dt, *J* = 8.2, 1.0 Hz), 7.45-7.38 (2H, m), 7.28 (1H, ddd, *J* = 8.2, 6.4, 1.3 Hz), 4.45 (2H, t, *J* = 7.2 Hz, CH₂), 4.37 (2H, dt, ²*J*_{HF} = 47.3 Hz, ³*J*_{HH} = 6.0 Hz, CH₂F), 4.00 (3H, s, CH₃), 2.02-1.95 (2H, m, CH₂), 1.74-1.61 (2H, m, CH₂), 1.46-1.38 (2H, m, CH₂). All physical properties and spectral data were consistent with those reported.¹³

1-(5-fluoropentyl)-1*H*-indazole-3-carboxylic acid (23). To a solution of **22** (198 mg, 0.75 mmol) in MeOH (7.5 mL) was added 1 M aq. NaOH (3.0 mL) in a single portion, and the solution stirred at ambient temperature for 16 h. The solvent was evaporated under reduced pressure, the crude material dissolved in H₂O (30 mL), and the pH adjusted to 2 with 10 M aq. HCl. The aqueous phase was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (5 mL), dried (Na₂SO₄), and the solvent evaporated under reduced pressure to afford **23** (182 mg, 97%). m.p. 80–82 °C; (lit. m.p. 80–82 °C); ¹H NMR (400 MHz, CDCl₃, 298 K): δ 8.27 (1H, dt, *J* = 8.2, 1.0 Hz, CH), 7.52-7.46 (2H, m, CH), 7.37 (1H, ddd, *J* = 8.2, 6.2, 1.7 Hz, CH), 4.53 (2H, t, *J* = 7.2 Hz, CH₂), 4.44 (2H, dt, ²*J*_{HF} = 47.3 Hz, ³*J*_{HH} = 5.9 Hz, CH₂F), 2.10-2.02 (2H, m, CH₂), 1.80-1.67 (2H, m, CH₂), 1.52-1.44 (2H, m, CH₂). All physical properties and spectral data were consistent with those reported.¹³

QTOF LC-MS/MS acquisition and analysis method. All samples were analyzed using an

Agilent LC 1260 Infinity Binary Liquid Chromatograph (LC) System attached to an Agilent 6550 iFunnel Quadrupole Time-of-Flight Mass Spectrometer (QTOF/MS) 6550 (Agilent Technologies, Santa Clara, CA). An Agilent jet stream electrospray ionization (ESI) source with a dual nebulizer that allows constant introduction of reference mass during sample run was used to ionize sample organic components in positive mode.

Each sample was prepared from a crystalline or resin aliquot of purified synthetic product and diluted to a final concentration of 100 and 500 ng/mL in 10% LC-MS grade acetonitrile (Honeywell B&J, Muskegon, MI); two concentrations were injected to elucidate potential solvent impurities or instrument artifacts. In each sample run, 2.5 μ L was injected into an Agilent Poroshell 120 C-18 column (2.1 $\times$ 100 mm, 2.7 μ m) maintained at 50 °C. Chromatographic separation was achieved by gradient elution using LC-MS grade water (Honeywell B&J, Muskegon, MI) with 0.05% formic acid and 5 mM ammonium formate as mobile phase A, and acetonitrile with 0.05% formic acid as mobile phase B. The elution gradient used was 0–0.5 min = 5% B; 1.5 min = 30% B; 4.5 min = 70% B; 7.5 min = 100% B; 7.5–10 min = 100% B; and 10.01–12 min = 5% B.

Ionization of chromatographic eluates was induced on the QTOF/MS using an ESI source in the positive mode operated under the following conditions: gas temperature at 225 °C; sheath gas temperature at 350 °C; drying gas flow at 14 L/min; sheath gas flow at 11 L/min; nebulizer pressure at 40 psig; voltage cap at 3000 V; and nozzle voltage at 500 V. Data acquisition was run at 2 GHz in extended dynamic range mode. Both TOF/MS and MS/MS spectra were collected in automated MS/MS mode using 500 arbitrary units as threshold for inducing MS/MS data collection. An active exclusion was used after 1 spectra, with a release time of 0.05 mins. Each

sample was run in triplicate.

The total ion chromatogram (TIC) obtained from the LC-QTOF/MS run was analyzed using Agilent MassHunter Qualitative Analysis software (Agilent Technologies, Sta. Clara, CA). A search was done using the chemical formula of the expected material to confirm the identity and measure retention time of the major chromatogram peak. To confirm, the following criteria were imposed for a compound match: mass error ≤ 10 ppm; target score ≥ 70 (indication of isotopic pattern match) for peaks that did not exhibit detector saturation; and the presence of at least one expected fragment ion peak in its MS/MS spectra. MS/MS spectra were captured to assess the unique fragmentation of each parent cannabinoid.

***In vitro* cannabinoid receptor binding experiments.** Experiments utilized human CB₁ or CB₂ tagged at the *N*-terminus with three haemagglutinin sequences (HA-hCB₁, HA-hCB₂) stably transfected into HEK 293.^{44,45} HEK 293 were cultivated in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and zeocin, (250 μ g/mL). Cells were maintained in 5% CO₂ at 37 °C in a humidified atmosphere. Cells were grown in 75 cm² flasks and passaged when 80-90% confluent.

HEK 293-hCB₁ or HEK293-hCB₂ cells were grown to 90–100% confluence in 175 cm² flasks and harvested in ice-cold phosphate buffered saline (PBS) with 5 mM EDTA. Cells were centrifuged at 200 $\times$ g for 10 minutes and the pellet frozen at –80 °C until required. Pellets were thawed with Tris-sucrose buffer (50 mM Tris-HCl, pH 7.4, 200 mM sucrose, 5 mM MgCl₂, 2.5 mM EDTA) and homogenized with a glass homogenizer. The homogenate was centrifuged at 1000 $\times$ g for 10

minutes at 4 °C and the pellet discarded. The supernatant was then centrifuged at $27\,000 \times g$ for 30 minutes at 4 °C. The final pellet was resuspended in a minimal volume of Tris-sucrose buffer, and aliquoted then stored at -80 °C. Protein concentration was determined using the DC protein assay kit (Bio-Rad, Hercules, CA, USA) following the manufacturers protocol. Initial compound screening involved resuspension of cell membranes (5-10 µg/point) in binding buffer (50 mM HEPES, 1 mM MgCl₂, 1 mM CaCl₂, 0.2% (w/v) bovine serum albumin (BSA, ICP Bio, New Zealand, pH 7.4) and incubation with [³H]SR141716A (1.25 nM, specific activity 55 Ci/mmol) for CB₁ or [³H]CP55,940 (1.0 nM, specific activity 175 Ci/mmol) for CB₂ (PerkinElmer, Waltham, MA, USA) and 10 µM of the test compound at 30 °C for 60 minutes. Test compounds were all dissolved in DMSO at 10 mM, and DMSO addition was controlled for in all assay points. GF/C Harvest Plates (PerkinElmer) were pre-soaked for one hour in 0.1% polyethylenimine and then washed with 200 µL ice cold wash buffer (50 mM HEPES pH 7.4 500 mM NaCl, 0.1 % BSA) prior to filtration of samples, which were then subject to 3 additional 200 µL washes in ice cold wash buffer. Harvest plates were dried overnight at 24 °C, and then 50 µL of scintillation fluid was added to each well and plates were read 30 minutes later for 2 minutes per well in a Microbeta Trilux (PerkinElmer). Screening assays were performed in duplicate, repeating assays for each mediator 3 or more times. Non-specific binding was defined as binding that occurred in the presence of 10 µM CP 55,940. Compounds that produced >60% displacement at 10 µM were further characterized to define affinity. Competitive binding curves were produced by incubating the membranes and radioligand with a range of concentrations of test compound. Data was analyzed using GraphPad Prism, curves are generated using a One site-fit K_i Competitive Binding function with K_d of [³H]SR141716A constrained to 1 nM at CB₁, and [³H]CP 55,940 to 1 nM at CB₂.

***In vitro* cannabinoid receptor functional activity assay.** Mouse AtT20 neuroblastoma cells stably transfected with human CB₁ or human CB₂ have been previously described.⁴³ and were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U penicillin/streptomycin, and 80 µg/mL hygromycin (InvivoGen, San Diego, CA, USA). Cells were passaged at 80% confluency as required. Cells for assays were grown in 75 cm² flasks and used at 90% confluence. The day before the assay cells were detached from the flask with trypsin/EDTA (Sigma) and resuspended in 10 mL of Leibovitz's L-15 media supplemented with 1% FBS, 100 U penicillin/streptomycin and 15 mM glucose. The cells were plated in volume of 90 µL in black walled, clear bottomed 96-well microplates (Corning) which had been precoated with poly-L-lysine (Sigma, Australia). Cells were incubated overnight at 37 °C in ambient CO₂.

Membrane potential was measured using a FLIPR Membrane Potential Assay kit (blue) from Molecular Devices, as described previously.⁴⁶ The dye was reconstituted with assay buffer of composition (mM): NaCl 145, HEPES 22, Na₂HPO₄ 0.338, NaHCO₃ 4.17, KH₂PO₄ 0.441, MgSO₄ 0.407, MgCl₂ 0.493, CaCl₂ 1.26, glucose 5.56 (pH 7.4, osmolarity 315 ± 5). Prior to the assay, cells were loaded with 90 µL/well of the dye solution without removal of the L-15, giving an initial assay volume of 180 µL/well. Plates were then incubated at 37 °C at ambient CO₂ for 45 min. Fluorescence was measured using a FlexStation 3 (Molecular Devices) microplate reader with cells excited at a wavelength of 530 nm and emission measured at 565 nm. Baseline readings were taken every 2 s for at least 2 min, at which time either drug or vehicle was added in a volume of 20 µL. The background fluorescence of cells without dye or dye without cells was negligible.

Changes in fluorescence were expressed as a percentage of baseline fluorescence after subtraction of the changes produced by vehicle addition. The final concentration of DMSO was 0.1%.

Data were analyzed with PRISM (GraphPad Software Inc., San Diego, CA), using four-parameter nonlinear regression to fit concentration-response curves. In all plates, a maximally effective concentration of CP 55,940 was added to allow for normalization between assays.

***In vivo* pharmacological assessment of 5F-PY-PICA and 5F-PY-PINACA.** Two cohorts of 4 adult male C57BL/6J mice (Animal Resources Centre, Perth, Australia) were used for biotelemetric assessment of body temperature. The mice weighed between 20.5 and 28.5 g on arrival, and were singly housed in a climate-controlled testing room (23 ± 1 °C) on a 12 h light/dark cycle (lights on from 07:00 to 19:00). Water and standard rodent chow were provided ad libitum. All experiments were approved by The University of Sydney Animal Ethics Committee.

Biotelemetry transmitters (model TA-F10, Data Sciences International, St. Paul, MN) were implanted as previously described.¹³ The transmitter was implanted according to the manufacturers protocol into the peritoneal cavity following anesthetization with isoflurane (3% induction, 1-2% maintenance). The wound was sutured closed and data collection commenced after 10 days of recovery.

The mice were habituated over multiple days to injections of vehicle (a solution composed of 7.8% polysorbate 80 and 92.2% physiological saline). Injection always occurred at a set time of day

(10:00 am). Each cohort received injections of each compound in an ascending dose sequence (0.3, 1, 3, and 10 mg/kg). This ascending sequence was used in order to minimize the risk posed to the animals in assessing hitherto untested compounds. Two washout (drug free) days were given between each dose to limit development of tolerance or carryover effects.

Body temperature data was gathered continuously at 1000 Hz and organized into 15 minute bins using Dataquest A.R.T. software (version 4.3, Data Sciences International, St. Paul, MN), and analysed using PRISM (version 7, Graphpad Software Inc., San Diego, CA).¹³

Results and discussion. The synthesis of 5F-PY-PICA (**5**) and related analogues **7–15** is shown in Figure 2. Using a general procedure, indole (**15**) was first alkylated with the appropriate alkyl bromide, converted to the corresponding 3-trifluoroacetylindole, and hydrolyzed to the carboxylic acid (**16–20**). The relevant carboxylic acid **16–20** was converted to the corresponding acid chloride using oxalyl chloride, and treated with pyrrolidine, piperidine, azepane, diethylamine, or dimethylamine to furnish amides **5** and **7–14**.

[APPROXIMATE PLACEMENT OF FIGURE 2]

The synthesis of 5F-PY-PINACA (**6**) required a slightly different route and is depicted in Figure 3. Methyl 1*H*-indazole-3-carboxylate (**21**) was deprotonated with potassium *tert*-butoxide, and then treated with 1-bromo-5-fluoropentane, to regioselectively yield the desired 1-alkylated indole-3-carboxylate (**22**) as previously described.¹³ Saponification of **22** afforded acid **23**, which was subsequently coupled with pyrrolidine using EDC-HOBt to give **6**. Attempts to form **6** by

converting **23** to the corresponding acid chloride and treating with pyrrolidine, as described for the indoles **5** and **7–14** above, were unsuccessful.

[APPROXIMATE PLACEMENT OF FIGURE 3]

5F-PY-PICA, 5F-PY-PINACA, and analogues **7–14** were analyzed using melting point range determinations, ^1H and ^{13}C nuclear magnetic resonance (NMR) spectroscopy, and liquid chromatography–quadrupole time-of-flight–mass spectrometry (LC-QTOF-MS). Full details of these analyses are provided in the experimental section. The mass spectra and fragment assignments for 5F-PY-PICA and 5F-PY-PINACA from LC-QTOF-MS/MS analysis are shown in Figures 4a and 4b, respectively. The QTOF mass fragmentation profiles of 5F-PY-PICA and 5F-PY-PINACA were similar, with molecular ions and fragments arising from scission of the amide C-N bond observed in each case. The base peak for 5F-PY-PICA was the molecular ion (m/z 303.1864, 100%), and an ion consistent with loss of pyrrolidine was next most abundant (m/z 232.1127, 55%). The reverse was observed for 5F-PY-PINACA, with the acylium ion resulting from amide C-N bond scission occurring as the base peak (m/z 233.1085, 100%), and the molecular ion as the next most abundant species (m/z 304.1799, 54%). For 5F-PY-PICA, the only other abundant fragment (>10%) was m/z 98.0595 (37%), likely formed from cleavage of the indole C3-amide bond. Other minor peaks were consistent with amide cleavage and concomitant indole N1 dealkylation (m/z 144.0426, 8%) or defluorination (m/z 283.1804, 3%).

5F-PY-PICA, 5F-PY-PINACA, and analogues **7–14** were screened in competitive radioligand binding assays and fluorescence-based functional assays against CB₁ and CB₂ receptors (Table 1).

Surprisingly, despite the detection of 5F-PY-PICA and 5F-PY-PINACA as putative NPS due to their presence in drug markets, neither compound exhibited high affinity for CB₁ (or CB₂) receptors, with less than 60% displacement of tritiated ligand for each compound at each receptor. Additionally, analogues **7–14** also demonstrated minimal displacement of [³H]SR141716A from CB₁, however, 5F-PY-PICA and 5F-PY-PINACA showed moderate affinities for CB₂ ($K_i = 1.73 \mu\text{M}$ and $0.65 \mu\text{M}$, respectively). There were also clear structure-affinity trends for analogues **7–14**, with expansion of the pyrrolidine ring of 5F-PY-PICA by one (piperidine **7**, $K_i = 363 \text{ nM}$) or two carbon atoms (azepane **8**, $K_i = 102 \text{ nM}$) increasing CB₂ affinity.

Symmetrical scission of the pyrrolidine ring of 5F-PY-PICA to the *N,N*-diethyl analogue also improved CB₂ affinity (**9**, $K_i = 1.02 \mu\text{M}$), while further truncation did not (*N,N*-dimethyl, **10**, $K_i > 10 \mu\text{M}$). Taken together, the data suggest that 1-(5-fluoropentyl)-1*H*-indole-3-carboxamide is a suitable scaffold for the development of CB₂ agonists, subject to sufficient steric or lipophilic contribution from pendant amide substituents.

Replacing the 5-fluoropentyl group of 5F-PY-PICA with other pendant motifs commonly seen in SCRAAs (**12–14**) had little effect on CB₂ binding, conferring micromolar activity in all cases ($K_i = 1.07\text{--}3.55 \mu\text{M}$) except **11** ($K_i > 10 \mu\text{M}$).

CP55,940 produced a hyperpolarization of AtT20-CB₁ cells with a pEC_{50} of 7.76 ± 0.4 , and a maximum decrease in fluorescence of $33 \pm 1 \%$. At $10 \mu\text{M}$, only **14** ($50 \pm 4\%$) and **8** ($40 \pm 4\%$) produced responses that were a substantial fraction of that produced by a maximally effective concentration of CP55,940 ($1 \mu\text{M}$). CP55,940 hyperpolarized AtT20-CB₂ cells with a pEC_{50} of

7.45 ± 0.03 , and a maximum decrease in fluorescence of $32 \pm 1\%$. Several ligands produced substantial hyperpolarizations of AtT20-CB₂ cells, but none had a maximum effect greater than 75% of CP55,940 at 1 μ M. The largest activation of CB₂ was induced by **8** ($72 \pm 3\%$).

The *in vitro* pharmacological profiles of 5F-PY-PICA and 5F-PY-PINACA indicate that these putative SCRAs have very low affinity and efficacy at CB₁ receptors, and are unlikely to be psychoactive in humans. Similar to many SCRA NPS, both 5F-PY-PICA and 5F-PY-PINACA had substantial activity at CB₂ receptors, but this is unlikely to mediate any discernable effects on mood in people.

To further characterize these compounds, and determine if they could be metabolized into active cannabinoids, we examined the effects of 5F-PY-PICA and 5F-PY-PINACA in mice using biotelemetry. The pharmacological effects of numerous SCRAs have been described in mice and rats, and include robust hypothermia, bradycardia, and hypolocomotion mediated by central CB₁ agonist activity.⁴⁷⁻⁵¹ As anticipated from the *in vitro* pharmacological data, neither 5F-PY-PICA nor 5F-PY-PINACA produced physiological effects consistent with central CB₁ activity, and hypothermic effects were not observed in mice at doses up to 10 mg/kg (Figure 5). Many SCRAs, including JWH-018, AB-FUBINACA, MDMB-FUBINACA, and 5F-CUMYL-P7AICA, elicit hypothermic effects at doses of 1 mg/kg or below in this rodent model via a CB₁ receptor-mediated mechanism.^{13,43,52} Therefore, it can be concluded that neither 5F-PY-PICA nor 5F-PY-PINACA exhibit the *in vitro* and *in vivo* cannabimimetic profiles shared by SCRA NPS. This does not preclude, of course, the possibility of psychoactive effects generated through non-cannabinoid mechanisms.

Conclusion: Despite their detection in drug markets in 2015, 5F-PY-PICA, 5F-PY-PINACA, and several analogues exhibited low affinity and efficacy at CB₁ and CB₂ receptors *in vitro*. Moreover, 5F-PY-PICA and 5F-PY-PINACA failed to elicit the hypothermic, bradycardic, and hypolocomotive effects potently induced by other SCRA NPS. Taken together, the *in vitro* and *in vivo* profiles of 5F-PY-PICA and 5F-PY-PINACA cast doubt on their classification as SCRAs, although NPS designation by non-cannabinoid mechanisms cannot be excluded.

Acknowledgement: Iain S. McGregor and Mark Connor gratefully acknowledge financial support from the Australian National Health and Medical Research Council (NHMRC Project Grant 1107088).

References

1. United Nations Office on Drugs and Crime. World Drug Report 2018. United Nations publication, Sales No. E.18.XI.9 2018. Available at <http://www.unodc.org/wdr2018>. Accessed 4 July 2018.
2. Banister SD, Connor M. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution. *Handb Exp Pharmacol*. 2018. https://doi.org/10.1007/164_2018_144.
3. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? *J Mass Spectrom*. 2009;44(5):832-837. <https://doi.org/10.1002/jms.1558>.

4. Dresen S, Ferreiros N, Putz M, Westphal F, Zimmermann R, Auwarter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. *J Mass Spectrom.* 2010;45(10):1186-1194. <https://doi.org/10.1002/jms.1811>.
5. Banister SD, Connor M. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins. *Handb Exp Pharmacol.* 2018. https://doi.org/10.1007/164_2018_143.
6. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y. New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. *Forensic Toxicol.* 2013;31(1):93-100. <https://doi.org/10.1007/s11419-012-0171-4>.
7. Shevyryn V, Melkozerov V, Nevero A, et al. Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group. *Anal Bioanal Chem.* 2015;407(21):6301-6315. <https://doi.org/10.1007/s00216-015-8612-7>.
8. Angerer V, Bisel P, Moosmann B, Westphal F, Auwarter V. Separation and structural characterization of the new synthetic cannabinoid JWH-018 cyclohexyl methyl derivative "NE-CHMIMO" using flash chromatography, GC-MS, IR and NMR spectroscopy. *Forensic Sci Int.* 2016;266:e93-e98. <https://doi.org/10.1016/j.forsciint.2016.05.031>.
9. Blakey K, Boyd S, Atkinson S, et al. Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer

- drugs in herbal incense. *Forensic Sci Int.* 2016;260:40-53.
<https://doi.org/https://doi.org/10.1016/j.forsciint.2015.12.001>.
10. McLaughlin G, Morris N, Kavanagh PV, et al. The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer. *Drug Test Anal.* 2016;8(9):920-929.
<https://doi.org/10.1002/dta.1864>.
 11. Ernst L, Brandhorst K, Papke U, et al. Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: Update of the German situation in early 2017. *Forensic Sci Int.* 2017;277:51-58. <https://doi.org/10.1016/j.forsciint.2017.05.019>.
 12. Angerer V, Mogler L, Steitz JP, et al. Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE. *Drug Test Anal.* 2018;10(3):597-603. <https://doi.org/10.1002/dta.2237>.
 13. Banister SD, Adams A, Kevin RC, et al. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold hopping analogue of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. *Drug Test Anal.* 2018;0(ja). <https://doi.org/10.1002/dta.2491>.
 14. Guillou C, Reniero F, Lobo Vicente J, et al. Collaboration of the Joint Research Centre and European Customs Laboratories for the Identification of New Psychoactive Substances. *Curr Pharm Biotechnol.* 2018;19(2):91-98.
<https://doi.org/10.2174/1389201019666180523122717>.
 15. Wiley JL, Marusich JA, Lefever TW, et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Delta9-

- Tetrahydrocannabinol-Like Effects in Mice. *J Pharmacol Exp Ther*. 2015;354(3):328-339.
<https://doi.org/10.1124/jpet.115.225326>.
16. Marusich JA, Wiley JL, Lefever TW, Patel PR, Thomas BF. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists. *Neuropharmacology*. 2018;134:73-81. <https://doi.org/10.1016/j.neuropharm.2017.10.041>.
 17. Maeda H, Nagashima E, Hayashi YK, Kikura-Hanajiri R, Yoshida K. MDMB-CHMICA induces thrashing behavior, bradycardia, and slow pressor response in a CB1- and CB2-receptor-dependent manner in conscious rats. *Forensic Toxicol*. 2018;36(2):313-319.
<https://doi.org/10.1007/s11419-018-0405-1>.
 18. Schoeder CT, Hess C, Madea B, Meiler J, Muller CE. Pharmacological evaluation of new constituents of "Spice": synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. *Forensic Toxicol*. 2018;36(2):385-403.
<https://doi.org/10.1007/s11419-018-0415-z>.
 19. Theunissen EL, Hutten N, Mason NL, et al. Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. *Br J Pharmacol*. 2018;175(1):18-28.
<https://doi.org/10.1111/bph.14066>.
 20. Trecki J, Gerona RR, Schwartz MD. Synthetic Cannabinoid-Related Illnesses and Deaths. *N Engl J Med*. 2015;373(2):103-107. <https://doi.org/10.1056/NEJMp1505328>.
 21. Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. *Forensic Sci Int*. 2016;261:e5-10. <https://doi.org/10.1016/j.forsciint.2016.02.024>.

22. Labay LM, Caruso JL, Gilson TP, et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. *Forensic Sci Int.* 2016;260:31-39. <https://doi.org/10.1016/j.forsciint.2015.12.046>.
23. Shanks KG, Clark W, Behonick G. Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA. *J Anal Toxicol.* 2016;40(3):236-239. <https://doi.org/10.1093/jat/bkv142>.
24. Shanks KG, Behonick GS. Death after use of the synthetic cannabinoid 5F-AMB. *Forensic Sci Int.* 2016;262:e21-24. <https://doi.org/10.1016/j.forsciint.2016.03.004>.
25. Springer YP, Gerona R, Scheunemann E, et al. Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016. *MMWR Morb Mortal Wkly Rep.* 2016;65(40):1108-1111. <https://doi.org/10.15585/mmwr.mm6540a4>.
26. Westin AA, Frost J, Brede WR, et al. Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA. *J Anal Toxicol.* 2016;40(1):86-87. <https://doi.org/10.1093/jat/bkv110>.
27. Angerer V, Jacobi S, Franz F, Auwarter V, Pietsch J. Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. *Forensic Sci Int.* 2017;281:e9-e15. <https://doi.org/10.1016/j.forsciint.2017.10.042>.
28. Backberg M, Tworek L, Beck O, Helander A. Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project. *J Med Toxicol.* 2017;13(1):52-60. <https://doi.org/10.1007/s13181-016-0584-2>.
29. Meyyappan C, Ford L, Vale A. Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist. *Clin Toxicol.* 2017;55(2):151-152. <https://doi.org/10.1080/15563650.2016.1227832>.

30. Kasper AM, Ridpath AD, Gerona RR, et al. Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015). *Clin Toxicol.* 2018;1-9. <https://doi.org/10.1080/15563650.2018.1485927>.
31. Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. *Forensic Toxicol.* 2013;32(1):105-115. <https://doi.org/10.1007/s11419-013-0217-2>.
32. Adam JM, Cairns J, Caulfield W, et al. Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists. *Medchemcomm.* 2010;1(1):54-60. <https://doi.org/10.1039/c0md00022a>.
33. European Monitoring Centre for Drugs and Drug Addiction EMCDDA–Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA. Publications Office of the European Union, Luxembourg, 2016. <https://doi.org/10.2810/932574>.
34. Mardal M, Annaert P, Noble C, Oorts M, Linnet K. Metabolism of the synthetic cannabinoid 5F-PY-PICA by human and rat hepatocytes and identification of biliary analytical targets by directional efflux in sandwich-cultured rat hepatocytes using UHPLC-HR-MS/MS. *J Pharm Biomed Anal.* 2018;149:296-307. <https://doi.org/10.1016/j.jpba.2017.11.027>.
35. Zawilska JB, Wojcieszak J. α -Pyrrolidinophenones: a new wave of designer cathinones. *Forensic Toxicol.* 2017;35(2):201-216. <https://doi.org/10.1007/s11419-016-0353-6>.

36. Fabregat-Safont D, Fornis I, Ventura M, et al. Identification and characterization of a putative new psychoactive substance, 2-(2-(4-chlorophenyl)acetamido)-3-methylbutanamide, in Spain. *Drug Test Anal.* 2017;9(7):1073-1080. <https://doi.org/10.1002/dta.2182>.
37. Fong CW, Grant HG. The effect of ring size in N-benzoyl saturated heterocyclic amides. *Aus J Chem.* 1981;34(11):2307-2312. <https://doi.org/10.1071/ch9812307>.
38. European Project RESPONSE. Analytical Report 5F-PY-PICA (C₁₈H₂₃FN₂O) 1-(5-fluoropentyl)-3-(pyrrolidine-1-carbonyl). National Forensic Laboratory, Ljubljana, Slovenia. 2015. Available at https://www.policija.si/apps/nfl_response_web/seznam.php. Accessed 29 September 2018.
39. European Project RESPONSE. Analytical Report 5F-PY-PINACA (C₁₇H₂₂FN₃O) [1-(5-fluoropentyl)indazol-3-yl]-pyrrolidin-1-yl-methanone. National Forensic Laboratory, Ljubljana, Slovenia. 2015. Available at https://www.policija.si/apps/nfl_response_web/seznam.php. Accessed 29 September 2018.
40. Longworth M, Banister SD, Boyd R, et al. Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. *ACS Chem Neurosci.* 2017;8(10):2159-2167. <https://doi.org/10.1021/acscchemneuro.7b00267>.
41. Banister SD, Olson A, Winchester M, et al. The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. *Drug Test Anal.* 2018;10(7):1099-1109. <https://doi.org/10.1002/dta.2362>.

42. Banister SD, Stuart J, Kevin RC, et al. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. *ACS Chem Neurosci.* 2015;6(8):1445-1458. <https://doi.org/10.1021/acschemneuro.5b00107>.
43. Banister SD, Longworth M, Kevin R, et al. Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. *ACS Chem Neurosci.* 2016;7(9):1241-1254. <https://doi.org/10.1021/acschemneuro.6b00137>.
44. Grimsey NL, Goodfellow CE, Dragunow M, Glass M. Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. *Biochim Biophys Acta Mol Cell Res.* 2011;1813(8):1554-1560. <https://doi.org/10.1016/j.bbamcr.2011.05.010>.
45. Finlay DB, Cawston EE, Grimsey NL, et al. G α s signalling of the CB1 receptor and the influence of receptor number. *Br J Pharmacol.* 2017;174(15):2545-2562. <https://doi.org/doi:10.1111/bph.13866>.
46. Knapman A, Santiago M, Du YP, Bennallack PR, Christie MJ, Connor M. A continuous, fluorescence-based assay of mu-opioid receptor activation in AtT-20 cells. *J Biomol Screen.* 2013;18(3):269-276. <https://doi.org/10.1177/1087057112461376>.
47. Canazza I, Ossato A, Vincenzi F, et al. Pharmacotoxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. *Hum Psychopharmacol.* 2017;32(3):e2601. <https://doi.org/10.1002/hup.2601>.

48. Gatch MB, Forster MJ. Delta(9)-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats. *Psychopharmacology*. 2018;235(3):673-680. <https://doi.org/10.1007/s00213-017-4783-6>.
49. Schindler CW, Gramling BR, Justinova Z, Thorndike EB, Baumann MH. Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats. *Drug Alcohol Depend*. 2017;179:387-394. <https://doi.org/10.1016/j.drugalcdep.2017.07.029>.
50. Gamage TF, Farquhar CE, Lefever TW, et al. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. *J Pharmacol Exp Ther*. 2018;365(2):437-446. <https://doi.org/10.1124/jpet.117.246983>.
51. Schreiber S, Bader M, Lenchinski T, et al. Functional effects of synthetic cannabinoids versus Delta(9) -THC in mice on body temperature, nociceptive threshold, anxiety, cognition, locomotor/exploratory parameters and depression. *Addict Biol*. 2018;0(0). <https://doi.org/10.1111/adb.12606>.
52. Banister SD, Moir M, Stuart J, et al. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. *ACS Chem Neurosci*. 2015;6(9):1546-1559. <https://doi.org/10.1021/acschemneuro.5b00112>.

Figure 1. Selected synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) and their prophetic analogues.

Figure 2. Reagents and conditions: (a)(i) NaH, R^1Br , DMF, 0 °C–rt, 1 h; (ii) $(CF_3CO)_2O$, 0 °C–rt, 1 h; (b) KOH, MeOH, PhMe, reflux, 2 h, 45–66% over 3 steps; (c) $(COCl)_2$, DMF (cat.), CH_2Cl_2 , 0 °C–rt, 2 h; (d) R^2R^3NH , Et_3N , CH_2Cl_2 , 0 °C–rt, 14 h, 63–89%.

Figure 3. Reagents and conditions: (a) KO^tBu , $\text{F}(\text{CH}_2)_5\text{Br}$, THF, $0\text{ }^\circ\text{C}$ –rt, 14 h, 81%; (b) 1 M aq. NaOH, MeOH, rt, 16 h, 97%; (c) EDC·HCl, HOBT·H₂O, pyrrolidine, Et₃N, DMF, rt, 13 h, 90%.

Figure 4. LC-QTOF-MS/MS mass spectra fragmentation patterns for (a) 5F-PY-PICA and (b) 5F-PY-PINACA.

Figure 5. Change in body temperature following intraperitoneal injection of (A) 5F-PY-PICA and (B) 5F-PY-PINACA relative to a baseline vehicle injection. The vertical dashed line denotes time of injection, and each data point represents the mean ($\pm$ SEM) change in body temperature of four mice. No hypothermic effects were observed at doses up to 10 mg/kg.

Table 1. Binding affinities and functional activities of compounds **5–14** at hCB₁ and hCB₂

receptors.^{a,b,c}

Compound	hCB ₁			hCB ₂		
	p <i>K</i> _i ± SEM (<i>K</i> _i nM)	pEC ₅₀ ± SEM (EC ₅₀ nM)	Max ± SEM (% CP 55,940)	p <i>K</i> _i ± SEM (<i>K</i> _i nM)	pEC ₅₀ ± SEM (EC ₅₀ nM)	Max ± SEM (% CP 55,940)
5F-PY-PICA (5)	<5 ^a	ND ^b	12 ± 3 ^c	5.76 ± 0.07 (1737)	6.47 ± 0.09 (338)	50 ± 3
5F-PY- PINACA (6)	<5 ^a	ND ^b	4 ± 3 ^c	6.19 ± 0.08 (645)	7.20 ± 0.11 (63.7)	64 ± 3
7	<5 ^a	ND ^b	24 ± 7 ^c	6.44 ± 0.03 (363)	7.44 ± 0.08 (36.3)	64 ± 3
8	<5 ^a	ND ^b	40 ± 4 ^c	6.99 ± 0.06 (102)	7.54 ± 0.08 (29.0)	72 ± 3
9	<5 ^a	ND ^b	0 ± 3 ^c	5.99 ± 0.09 (1023)	6.87 ± 0.14 (137)	53 ± 4
10	<5 ^a	ND ^b	9 ± 4 ^c	<5 ^a	ND ^b	11 ± 2 ^c

11	<5 ^a	ND ^b	16 ± 9 ^c	<5 ^a	6.33 ± 0.25 (473)	63 ± 9
12	<5 ^a	ND ^b	1 ± 3 ^c	5.49 ± 0.09 (3236)	6.63 ± 0.27 (236)	54 ± 7
13	<5 ^a	ND ^b	12 ± 2 ^c	5.45 ± 0.08 (3548)	6.44 ± 0.69 (367)	38 ± 13
14	<5 ^a	ND ^b	50 ± 4 ^c	5.97 ± 0.06 (1072)	6.87 ± 0.13 (136)	38 ± 3

^apK_i < 5, <60% displacement of tritiated compound at 10 μM; ^bpEC₅₀ not determined, <50% change in fluorescence at 10 μM; ^cResponse at 10 μM.